Constarium
← Search

Data · dataset · 2026

<p>The original data and code used in this study.</p>

Listed in NCL Data

<div> <p>Background</p><p>Non-invasive assessment of liver fibrosis is essential for managing chronic liver disease (CLD).

Description

Serum chitinase-3-like protein 1 (CHI3L1) has been recommended in recent guidelines, while FibroTouch is a domestically produced device for liver stiffness measurement (LSM). However, no study has directly compared their diagnostic performance in CLD patients.</p> <p>Methods</p><p>This retrospective study included 235 patients with CLD who underwent liver biopsy, FibroTouch examination, and laboratory testing (including CHI3L1 and routine blood parameters) at Hangzhou Xixi Hospital between October 2019 and December 2024.

Liver fibrosis was staged according to the Scheuer scoring system (S0–S4). The diagnostic performance of LSM, CHI3L1, and six serological models (aspartate aminotransferase-to-platelet ratio index [APRI], fibrosis-4 index [FIB-4], S-Index, Forns index, platelet ratio-to-RDW [PRP], and FIB-5) were evaluated using receiver operating characteristic (ROC) curve analysis, with liver biopsy as the reference standard.</p> <p>Results</p><p>Among the 235 patients, 125 (53.2%) had significant fibrosis (≥S2).

Read the rest (2 more)

LSM demonstrated excellent diagnostic accuracy, with area under the curve (AUROC) values of 0.86 for detecting significant fibrosis (≥S2), 0.91 for advanced fibrosis (≥S3), and 0.93 for cirrhosis (S4). CHI3L1 showed moderate diagnostic performance, with corresponding AUROC values of 0.72, 0.79, and 0.81. LSM exhibited the strongest correlation with histological staging (r = 0.70, p < 0.0001).

Among serological models, APRI and FIB‑4 showed relatively better performance, while FIB‑5 performed poorly.</p> <p>Conclusions</p><p>In this biopsy-proven CLD cohort, LSM demonstrated superior diagnostic performance for liver fibrosis assessment compared to CHI3L1 and six serological models, with the strongest correlation with histological staging. Given its better diagnostic efficacy and lower cost, LSM offers a practical advantage as a routine monitoring tool in clinical practice, particularly in resource-constrained settings.</p></div>

Links

Where it is published

Catalogue records · 1

Topics

From keywords
Biochemistry and cell biology · Chemistry · Earth & Environmental Science · Genetics · Infectious diseases · Life Sciences · Medicine & Health · Virology
Inferred from text
Disease 75%
Provenance · 1 source records, 14 field assertions
SourceKeyLast seenRaw
NCL Dataoai:figshare.com:article/340719539 h agoJSON v1
FieldAssertionExtractorEvidence
access_levelsource · data ncl ac ukconnector:data_ncl_ac_uk@1.0.0
concepts[disease].local:disease:diseaseenrichment · data ncl ac ukkeyword-concept-rules@1.0.0title+description (75%)
concepts[field].anzsrc:field:310706mapping · data ncl ac ukvocabulary-mapper@1.0.0keywords['Virology']
concepts[field].anzsrc:field:320211mapping · data ncl ac ukvocabulary-mapper@1.0.0keywords['Infectious Diseases']
concepts[field].anzsrc:group:3101mapping · data ncl ac ukvocabulary-mapper@1.0.0keywords['Cell Biology']
concepts[field].anzsrc:group:3105mapping · data ncl ac ukvocabulary-mapper@1.0.0keywords['Genetics']
concepts[field].local:field:chemistrymapping · data ncl ac ukconnector:data_ncl_ac_uk@1.0.0
concepts[field].local:field:earth-environmentalmapping · data ncl ac ukconnector:data_ncl_ac_uk@1.0.0
concepts[field].local:field:life-sciencesmapping · data ncl ac ukconnector:data_ncl_ac_uk@1.0.0
concepts[field].local:field:medicine-healthmapping · data ncl ac ukconnector:data_ncl_ac_uk@1.0.0
descriptionsource · data ncl ac ukconnector:data_ncl_ac_uk@1.0.0/metadata/dc/description
licensesource · data ncl ac ukconnector:data_ncl_ac_uk@1.0.0/metadata/dc/rights
publication_datesource · data ncl ac ukconnector:data_ncl_ac_uk@1.0.0
titlesource · data ncl ac ukconnector:data_ncl_ac_uk@1.0.0/metadata/dc/title